Viewbix Spotlights Quantum X Labs – Israel's Multi-Disciplinary Quantum Hub

Rhea-AI Summary

Viewbix (NASDAQ: VBIX) signed a definitive agreement to acquire between 85% and 100% of Quantum X Labs, an Israeli multi-disciplinary quantum hub, with closing expected within 90 days of the December 15, 2025 execution date.

Quantum X Labs houses five portfolio companies across navigation, error correction, algorithms for biomedicine, atomic clocks, and quantum security, and claims a quantum error correction approach that can cut computational overhead by up to 50%. The deal includes an expanding patent portfolio and existing sub-licensing collaboration with Ramot, and remains subject to regulatory approvals, stockholder consent, final due diligence, and customary closing conditions.

Positive

• Control stake of 85%–100% available to Viewbix
• 90-day expected close window from Dec 15, 2025
• Quantum error correction tech claims up to 50% overhead reduction
• Five complementary portfolio companies across quantum sectors
• Existing sub-license collaboration with Ramot (Tel Aviv University)

Negative

• Transaction is subject to regulatory approvals and stockholder consent
• Deal contingent on final due diligence and customary closing conditions
• No disclosed purchase price or financing terms in the announcement

Key Figures

Stake to be acquired 85%–100% Definitive agreement to acquire Quantum X Labs

Expected closing window 90 days Closing timeline from Dec 15, 2025 definitive agreement

Portfolio companies 5 companies Quantum X Labs’ quantum-focused portfolio

Error-correction efficiency Up to 50% reduction Quantum error correction patent overhead vs traditional methods

PIPE size $3 million Concurrent PIPE referenced in prior Quantum X Labs deal terms

Initial equity issuance cap 40% of capital Common stock and pre-funded warrants at closing

Common share component 19.99% of capital Exchange Shares portion of Quantum X consideration

Lock-up period 12 months Lock-up on exchange shares and warrant shares after closing

Market Reality Check

$1.53 Last Close

Volume Volume 203,653 is 1.32x the 20-day average of 153,907, indicating elevated interest pre-close. normal

Technical Shares at $1.53 are trading below the $3.80 200-day MA after a prolonged drawdown from the $12 52-week high.

Peers on Argus

VBIX gained 18.6% while peers were mixed: SCOR -3.42%, SJ -0.73%, but GIFT, FENG and ZDGE rose 5.77%, 2.45% and 3.47% respectively, pointing to a stock-specific move tied to the Quantum X Labs acquisition.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 22	Patent & acquisition update	Positive	-1.9%	Quantum X Labs provisional patent and reiteration of 85%–100% acquisition terms.
Dec 16	Definitive deal terms	Positive	-24.8%	Definitive agreement to acquire 85%–100% of Quantum X Labs with equity-heavy structure.
Nov 14	Revised acquisition terms	Positive	+2.5%	Updated term sheet reducing initial equity issuance to 40% with milestone earn-outs.
Nov 12	Asset sale & pivot	Positive	+1.8%	Sale of Cortex Media and disclosure of non-binding Quantum X Labs term sheet.
Nov 05	Private placement	Negative	-42.3%	$3.0 million private placement with units and warrants tied to Quantum acquisition.

Pattern Detected

Quantum X Labs deal and financing headlines have often faced selling, especially around large equity issuance, with only the refined terms update drawing a clear positive price reaction.

Recent Company History

Over the past few months, VBIX has systematically pivoted toward quantum technologies. A Nov 5, 2025 private placement of about $3.0 million and subsequent 8-K filings laid out progressively refined terms to acquire 85%–100% of Quantum X Labs, including equity and pre-funded warrant structures and milestone earn-outs. News on selling Cortex Media and Quantum’s provisional patent on Dec 22, 2025 reinforced this shift. Today’s announcement reiterates this strategic transition and expected closing within 90 days of the Dec 15, 2025 definitive agreement.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-08-05

VBIX has an active S-3 shelf filed on Aug 05, 2025, expiring on Aug 05, 2028. The filing is not yet effective and shows 0 recorded usages, but it provides a framework for future registered offerings once effective.

Market Pulse Summary

This announcement reiterates VBIX’s definitive agreement to acquire 85%–100% of Quantum X Labs, a hub with five quantum-focused portfolio companies and patented error‑correction technology claiming up to a 50% overhead reduction. It builds on prior disclosures of equity and warrant-based consideration and a related $3.0 million PIPE. Investors may monitor progress toward closing within 90 days, patent milestones, and any future use of the existing S-3 shelf for capital raising.

Key Terms

quantum error correction technical

"Quantum Error Correction: Addressing scalability issues in quantum computing with patented solutions..."

Quantum error correction is a set of methods for detecting and fixing mistakes in quantum computers by encoding fragile quantum information across multiple physical parts, much like using multiple copies or checksums to protect a sensitive digital file. For investors, it matters because reliable error correction is a key technical milestone that determines whether quantum machines can scale from experimental devices to practical tools that could disrupt computing, encryption, drug discovery and other industries.

markov chain monte carlo technical

"quantum-enhanced Markov Chain Monte Carlo methods that could revolutionize drug discovery..."

A Markov Chain Monte Carlo (MCMC) method is a way to simulate many possible outcomes from a complex probability model by taking a sequence of random steps that gradually explores the most likely scenarios, like a hiker using many short, guided walks to map an unexplored landscape. For investors it matters because MCMC helps quantify uncertainty and estimate probabilities for pricing, risk, and forecasts when formulas are too complex to solve directly, improving decisions under uncertainty.

AI-generated analysis. Not financial advice.

Tel Aviv, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- In a move poised to reshape the landscape of advanced technologies, Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), has solidified its commitment to quantum innovation by signing a definitive agreement to acquire up to 100%, but not less than 85%, of Quantum X Labs Ltd., Israel's multi-disciplinary quantum technology laboratory. This strategic acquisition, announced in mid-December 2025 and expected to close within the next few months, comes at a pivotal moment as quantum technologies transition from lab curiosities to high-impact commercial solutions. The potential acquisition provides deeper insight into Quantum X Labs' innovations, highlighting potential in the growing quantum sector.

Founded on the vision that quantum progress thrives through interdisciplinary convergence, Quantum X Labs has built a unique ecosystem uniting top-tier talent and cutting-edge research. Drawing from Israel's renowned academic powerhouses- including the Hebrew University of Jerusalem, Tel Aviv University, the Technion, and the Weizmann Institute—Quantum X Labs employs a multidisciplinary team of scientists, engineers, and researchers. This blend of theoretical expertise and practical engineering has enabled rapid translation of ideas into deployable technologies, positioning Quantum X Labs as a cornerstone of Israel's quantum sector and a rising player globally.

At the heart of Quantum X Labs' operations are five portfolio companies, each tackling a distinct quantum challenge:

• Quantum Navigation: Developing reliable systems for GPS-denied environments, essential for defense, autonomous vehicles, and remote operations.
• Quantum Error Correction: Addressing scalability issues in quantum computing with patented solutions that reduce computational overhead by up to 50% compared to traditional methods.
• Quantum Algorithmic Platforms: Focused on clinical and biomedical research, including a recent provisional patent for quantum-enhanced Markov Chain Monte Carlo methods that could revolutionize drug discovery by uncovering hidden biological structures in trial data.
• Next-Generation Atomic Clocks: Leveraging quantum principles for unprecedented precision in timing and synchronization applications.
• Quantum-Based Security: Protecting data, communications, and critical infrastructure against emerging threats.
  

This diversified approach not only mitigates risks but amplifies synergies, allowing advancements in one area to bolster others. For instance, Quantum X Labs's quantum error correction patent, sub-licensed in collaboration with Ramot (Tel Aviv University's technology transfer arm), supports fault-tolerant computing essential for all portfolio initiatives. Quantum X Labs has already demonstrated its international stature by participating in the world's largest quantum conference in Denmark last November, showcasing Israel's contributions to global innovation.

Viewbix believes that the timing of its potential acquisition couldn't be more opportune. As quantum computing matures, markets like personalized medicine and secure communications are projected to explode, with Quantum X Labs' IP portfolio- including multiple upcoming patent filings- poised to capture significant value.

For those eyeing the quantum boom, this potential acquisition highlights Quantum X Labs' strong foundation: a patented portfolio, elite talent, and a clear path to commercialization. As the deal progresses- subject to regulatory approvals, stockholder consent, and customary conditions-expect further milestones that could transform industries.

Viewbix recently signed a definitive agreement to acquire up to 100% (and not less than 85%) of Quantum X Labs, encompassing its expanding patent portfolio, including prior IP in quantum error correction. The acquisition is expected to close within 90 days of the date of execution of the definitive agreement, which was December 15, 2025, subject to final due diligence, regulatory approvals, the approval of the Company’s stockholders in accordance with applicable rules or regulations of the Nasdaq Stock Market LLC and customary closing conditions.

 About Viewbix Inc.

Viewbix, through certain of its subsidiaries Gix Media Ltd. and Metagramm Software Ltd., operates in the field of digital advertising. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software. The company offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

Viewbix’s technological tools allow advertisers and website owners to earn more from their advertising campaigns and generate additional profits from their websites.

For more information about Viewbix, visit https://view-bix.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and completion of the acquisition, the receipt of regulatory approvals, the receipt of approval by the Company’s stockholders and the satisfaction of closing conditions related to the acquisition. Because such statements deal with future events and are based on Viewbix’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Viewbix undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Viewbix is not responsible for the contents of third-party websites.

Investor Relations Contacts:
Michal Efraty
Investor Relations
michal@efraty.com

FAQ

What stake is Viewbix (VBIX) acquiring in Quantum X Labs and when will it close?

Viewbix agreed to acquire between 85% and 100% of Quantum X Labs, with closing expected within 90 days of the December 15, 2025 execution date, subject to approvals.

How could Quantum X Labs' patent on error correction affect VBIX shareholders?

The error correction patent claims up to a 50% reduction in computational overhead, which Viewbix says could strengthen its quantum IP and commercialization prospects.

What businesses does Quantum X Labs include in the acquisition for VBIX (VBIX)?

The lab comprises five portfolio companies: quantum navigation, error correction, algorithmic platforms for biomedicine, atomic clocks, and quantum-based security.

Are there regulatory or shareholder risks to the Viewbix (VBIX) acquisition of Quantum X Labs?

Yes; the transaction is explicitly subject to regulatory approvals, stockholder consent, final due diligence, and customary closing conditions.

Does the Viewbix (VBIX) announcement disclose a purchase price or financing for the Quantum X Labs deal?

No; the announcement does not disclose any purchase price, financing amounts, or consideration terms.

Will Viewbix (VBIX) acquire Quantum X Labs' existing IP collaborations?

Yes; the deal includes Quantum X Labs' expanding patent portfolio and references an existing sub-license collaboration with Ramot.